In the News


27 Winners Announced at the 19th Annual Medical Design Excellence Awards (MDEA) Award Ceremony
Winners selected for groundbreaking work in the medical technology field

NEWS PROVIDED BY
UBM Americas 
Jun 13, 2017, 17:58 ET
NEW YORK, June 13, 2017 /PRNewswire/ — The Medical Design Excellence Awards (MDEA), recognizing the technological achievements of medical device manufacturers, announced the 2017 winners at its annual awards ceremony on the evening of June 13. Produced by the Medical Device and Diagnostic Industry (MD+DI), the MDEAs have recognized innovation in medical product design and engineering. Awards are granted across nine categories, announcing gold, silver and bronze medal winners in each category, in addition to naming the best in show and revealing the 2017 readers’ choice winner.

Read the full press release.

In the News

Hampton-based ivWatch receives a $14.8 million round of funding
By Sandra J. Pennecke 
Jun 9, 2017

Gary Warren would like to type IV infiltration into a search engine in 10 years and find that the horrible images are all gone.

Warren, president and CEO of ivWatch LLC, a medical device firm based in Hampton, is working hard to solve the problems that occur when an IV infiltrates.

Infiltration occurs when fluid or medication leaks into the surrounding tissue and can be caused by improper placement or dislodgment of the IV. Read the full article.

Original article published in Inside Business on June 9, 2017.

In the News

ivWatch snags $14M+ for IV-monitoring device
by Amirah Al Idrus 
Jun 9, 2017

ivWatch, which markets a device that continuously monitors patients receiving intravenous lines, raised $14.8 million, which will boost its marketing and “strategic partner” activities.

Most hospital patients are given an IV line that delivers nutrients, fluid or medication. But the failure rate due to infiltration, or leakage, is estimated at more than 20%, according to ivWatch. Leakage of fluid or drugs into the surrounding tissue could result in complications as serious as tissue necrosis and amputation. Read the full article.

Original post published in FierceBiotech on June 9, 2017.

In the News

ivWatch raises $14.8m for infusion therapy tech
JUNE 7, 2017 by Sarah Faulkner

ivWatch said today that it closed a $14.8 million financing round to support the company’s direct go-to-market initiatives and strategic partners activities.

Undisclosed angel investors, family funds and a major hospital system invested in the round, according to the company.

“The support ivWatch has seen from our investors and partners has been incredible. They are committed to seeing our technology, research, science and team make a true impact on the problems related to peripheral IV failure,” president & CEO Gary Warren said in prepared remarks. “The momentum we are finding in the market is exciting, as healthcare providers see the benefits of improved patient safety and reduced risks associated with IV therapy.” Read the full article.

Original post published in Drug Delivery Business News on June 7, 2017.

ivWatch Closes $14.8 Million Funding Round

HAMPTON, VA. — June 7, 2017 — ivWatch LLC, a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy, today announced the closing of its latest funding round of $14.8 million from undisclosed angel investors, family funds and a major hospital system. The financing will support the company’s direct go-to-market initiatives and strategic partner activities.

“The support ivWatch has seen from our investors and partners has been incredible. They are committed to seeing our technology, research, science and team make a true impact on the problems related to peripheral IV failure,” says Gary P. Warren, President & CEO of ivWatch,LLC. “The momentum we are finding in the market is exciting, as healthcare providers see the benefits of improved patient safety and reduced risks associated with IV therapy.”

IV therapy is the most common invasive hospital procedure. Yet failure rates due to infiltration are pegged at more than 20 percent. Every failure of an IV results in a drug delivery error and carries the potential for reduced drug efficacy and physical harm. Complications range from skin redness, burning, tissue necrosis and compartment syndrome to possible limb amputation.

ivWatch technology is the first of its kind to offer a solution for continuously monitoring an IV site and assessing if drugs are actually being delivered to the vein without leakage. The ivWatch Model 400 is an FDA-cleared device that continuously monitors any patient’s peripheral IV for the early detection of these infiltration and extravasation events and helps clinicians manage the risk associated with IV therapy. The company also recently launched the ivWatch Original Equipment Manufacturer (OEM) Board to enable seamless integration of ivWatch’s groundbreaking IV infiltration detection technology with patient monitoring systems, infusion pumps and other devices. By integrating ivWatch technology into existing products, OEMs will be able to help healthcare customers deliver a higher level of patient care.

“ivWatch represents the entrepreneurial progress of our region,” says John Lawson, President and CEO of W.M. Jordan Company and Chairman of the Board at ivWatch, LLC. “The scientific, financial and business acumen of those involved with the company, from investors, board members and advisors to the employees, is remarkable. Every day the team moves one step closer to helping resolve the infiltration issue within our healthcare system.”

For more information about ivWatch and its revolutionary medical technologies, go to www.ivwatch.com/products.

MEDIA CONTACT: Leah Moore, leah.moore@ivwatch.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653

The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance.

In the News

ivWatch touts new OEM board for IV infiltration detection
May 25, 2017 By Danielle Kirsh

Hampton, Va. based ivWatch announced the launch of its ivWatch OEM board designed to enable seamless integration of its IV infiltration detection technology with patient monitoring systems, infusion pumps and other devices.

OEMs can help bring a higher level of patient care to patients and reduce risks that come from IV therapies by using ivWatch technology in existing products. Read the full article.

Original article published in Medical Design & Outsourcing on May 25, 2017.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest